Thanks to the research being done in CKid, we know that children diagnosed with chronic kidney disease progress over time to dialysis and transplantation. That makes it very important to address therapies which can mitigate the progression of chronic kidney disease.
Joining the show today is Tarak Srivastava, MD, he has been awarded R01 funding from the National Institutes of Health to work on targeting EP2, one of the four PGE2 receptors to mitigate hyperfiltration–mediated kidney injury as a way to delay the progression of chronic kidney disease in children born with congenital anomalies of kidney and urinary tract (CAKUT).
Selected Podcast
Mitigating Hyperfiltration-Mediated Kidney Injury
Featured Speaker:
Learn more about Tarak Srivastava, MD
Tarak Srivastava, MD
Tarak Srivastava, MD, Associate Professor of Pediatrics, University of Missouri-Kansas City School of Medicine and Director of the Nephrology Research Laboratory at Children’s Mercy, has been involved in both bench and clinical research for many years, and is one of a handful of investigators researching the role of biomechanical processes on the progression of chronic kidney disease. He received his medical degree and completed a residency in pediatrics at Seth GS Medical College, Bombay, India. Dr. Srivastava completed a fellowship in Pediatric Nephrology at Sydney Children’s Hospital, Sydney, Australia and at Children’s Mercy Kansas City. He is board certified in Pediatric and Pediatric Nephrology.Learn more about Tarak Srivastava, MD